FABRIS, BRUNO
 Distribuzione geografica
Continente #
NA - Nord America 18.445
EU - Europa 9.732
AS - Asia 7.845
SA - Sud America 922
AF - Africa 311
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 25
Totale 37.305
Nazione #
US - Stati Uniti d'America 18.171
SG - Singapore 2.928
PL - Polonia 2.846
CN - Cina 1.759
IT - Italia 1.542
SE - Svezia 1.264
UA - Ucraina 875
HK - Hong Kong 752
VN - Vietnam 742
BR - Brasile 734
DE - Germania 606
FI - Finlandia 497
KR - Corea 440
FR - Francia 411
GB - Regno Unito 371
TR - Turchia 349
RU - Federazione Russa 314
NL - Olanda 235
BD - Bangladesh 224
BG - Bulgaria 189
IE - Irlanda 189
IN - India 185
CA - Canada 134
MA - Marocco 121
MX - Messico 91
CH - Svizzera 79
BE - Belgio 68
JP - Giappone 66
AR - Argentina 60
ZA - Sudafrica 56
ES - Italia 55
CZ - Repubblica Ceca 49
IQ - Iraq 47
AT - Austria 40
SA - Arabia Saudita 38
EG - Egitto 33
PH - Filippine 29
ID - Indonesia 28
EC - Ecuador 27
MY - Malesia 26
PK - Pakistan 26
SN - Senegal 22
VE - Venezuela 22
DZ - Algeria 21
AU - Australia 19
CL - Cile 19
EU - Europa 18
JO - Giordania 17
CO - Colombia 16
IR - Iran 16
AZ - Azerbaigian 15
IL - Israele 15
TH - Thailandia 15
PY - Paraguay 14
RO - Romania 14
UZ - Uzbekistan 14
AE - Emirati Arabi Uniti 13
KZ - Kazakistan 13
BO - Bolivia 12
TN - Tunisia 11
ET - Etiopia 10
GR - Grecia 10
NP - Nepal 10
RS - Serbia 10
LT - Lituania 9
UY - Uruguay 9
AL - Albania 8
CR - Costa Rica 8
KE - Kenya 8
PE - Perù 8
TW - Taiwan 8
BY - Bielorussia 7
CY - Cipro 7
HU - Ungheria 7
LB - Libano 7
LK - Sri Lanka 7
NI - Nicaragua 7
GT - Guatemala 6
LV - Lettonia 6
OM - Oman 6
PA - Panama 6
TT - Trinidad e Tobago 6
CD - Congo 5
KG - Kirghizistan 5
LU - Lussemburgo 5
NZ - Nuova Zelanda 5
PT - Portogallo 5
QA - Qatar 5
DO - Repubblica Dominicana 4
KW - Kuwait 4
MM - Myanmar 4
NG - Nigeria 4
PS - Palestinian Territory 4
SI - Slovenia 4
XK - ???statistics.table.value.countryCode.XK??? 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AM - Armenia 3
AO - Angola 3
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
Totale 37.245
Città #
Warsaw 2.659
Ashburn 1.872
Singapore 1.728
Woodbridge 1.714
Fairfield 1.533
Houston 1.359
Ann Arbor 1.256
Chandler 1.223
San Jose 909
Jacksonville 765
Wilmington 763
Hong Kong 733
Seattle 627
Cambridge 499
Beijing 447
Seoul 434
Hefei 361
Trieste 323
Princeton 321
Boardman 320
Chicago 289
Los Angeles 269
Izmir 256
Columbus 226
Ho Chi Minh City 222
Munich 189
Sofia 186
Dublin 181
Lauterbourg 181
Hanoi 173
Dallas 172
Helsinki 169
The Dalles 164
Zgierz 163
Moscow 154
Milan 147
Council Bluffs 136
Santa Clara 125
Frankfurt am Main 123
New York 123
Dearborn 120
Düsseldorf 114
Casablanca 109
Buffalo 104
San Diego 86
London 82
São Paulo 74
Bern 69
Brussels 65
Phoenix 58
Orem 54
Shanghai 54
Des Moines 52
Tokyo 52
Memphis 51
Rome 51
Falls Church 48
Washington 48
Atlanta 47
Dong Ket 46
North Bergen 44
Montreal 42
Jinan 41
Turku 41
Salt Lake City 40
Amsterdam 39
Brooklyn 38
Nanjing 35
Da Nang 34
Haiphong 33
Kocaeli 33
Norwalk 33
Johannesburg 32
Redmond 31
Redondo Beach 31
Chennai 29
Nuremberg 29
Boston 28
Denver 28
Redwood City 28
Vienna 28
Guangzhou 27
Miano 27
Verona 26
Elk Grove Village 25
Toronto 25
Bremen 24
Lappeenranta 24
Prague 24
Tampa 24
Venezia 24
Mestre 23
Stockholm 23
Dakar 22
Mexico City 21
Mumbai 21
Rio de Janeiro 20
Ankara 19
Dhaka 19
Hangzhou 19
Totale 26.032
Nome #
The complex interplay between lipids, immune system and interleukins in cardio-metabolic diseases 628
A case report of hyponatremia after surgery for Conn's adenoma 538
A case report of malignant hypertension in a young woman 482
Aldosterone effects on glomerular structure and function 481
A new ultrasonographic instrument for measuring vessel wall shear stress. 478
Radiofrequency ablation compared to surgery for the treatment of benign thyroid nodules 478
Surgical and pathological changes after radiofrequency ablation of thyroid nodules 439
Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease 426
TRAIL Modulates the Immune System and Protects against the Development of Diabetes 423
Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease 423
Association between thyroid hormones and TRAIL 420
Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients 414
A prospective study on the efficacy of patient simulation in heart and lung auscultation 412
Cross-sex hormone therapy for gender dysphoria 394
Usefulness of core needle biopsy for the diagnosis of thyroid Burkitt's lymphoma: a case report and review of the literature 370
Albumin permeability in isolated glomeruli in incipient experimental diabetes mellitus. 343
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. 319
Patient satisfaction after thyroid RFA versus surgery for benign thyroid nodules: a telephone survey 317
Quantitative value of aldosterone-renin ratio for detection of aldosterone-producing adenoma: The Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) study 316
Angiotensin 1-7 significantly reduces diabetes-induced leukocyte recruitment both in vivo and in vitro 306
12-month efficacy of a single radiofrequency ablation on autonomously functioning thyroid nodules 303
Large-artery hemodynamics after acute alcohol administration in young, healthy volunteers 295
Partial thyroidectomy for papillary thyroid microcarcinoma: Is completion total thyroidectomy indicated? 292
Ambulatory Blood Pressure Monitoring-Derived Short-Term Blood Pressure Variability in Primary Aldosteronism 283
Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. 274
Innate immunity, through late complement components activation, contributes to the development of early vascular inflammation and morphologic alterations in experimental diabetes. 273
Radiofrequency ablation for benign thyroid nodules 273
Rationality in prophylactic central neck dissection in clinically node-negative (cN0) papillary thyroid carcinoma: Is there anything more to say? A decade experience in a single-center 273
Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma. 271
Angiotensin-converting enzyme 2 regulates renal atrial natriuretic peptide through angiotensin-(1-7) 271
Ambulatory Arterial Stiffness Indexes in Acromegaly. 265
Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension. 265
Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study 263
DOSE AND TIME-DEPENDENT APOPTOTIC EFFECTS BY ANGIOTENSIN II INFUSION ON LEFT VENTRICULAR CARDIOMYOCYTES. 262
Haemoconcentration, shear-stress increase and carotid artery diameter regulation after furosemide administration in older hypertensives 260
A pheochromocytoma with high adrenocorticotropic hormone and a silent lung nodule. 259
Systemic and regional haemodynamic effects of aortofemoral angiography 253
Exploratory case-control study on ACE2 expression in children with short stature 253
Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes 251
Influence of carotid atherosclerotic plaques on pulse wave assessment with arterial tonometry 251
Treatment with n-3 Polyunsaturated Fatty Acids Reverses Endothelial Dysfunction and Oxidative Stress in Experimental Menopause 251
Full-Thickness Skin Burn Caused by Radiofrequency Ablation of a Benign Thyroid Nodule 246
Baroreflex sensitivity and central hemodynamics after omega-3 polyunsaturated fatty acids supplementation in an animal model of menopause 244
ACE2 deficiency shifts energy metabolism towards glucose utilization 243
Antihypertensive activity of arylidenaminoguanidine derivatives. 239
Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term 239
Dyslipidemia and Diabetes Increase the OPG/TRAIL Ratio in the Cardiovascular System 237
Cardiac and nephroprotective effects of angiotensin converting enzyme inhibitor treatment in the renal ablation model. 236
Coexistence of chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Impact on presentation, management, and outcome 234
Supplementation of Omega-3 Polyunsaturated Fatty Acids Prevents Increase in Arterial Stiffness After Experimental Menopause 233
Baroreceptor-heart rate reflex sensitivity enhancement after urinary bladder distention in essential hypertensives 232
Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice 230
Acute effects of intravenous infusions of alcohol on baroreceptor sensitivity in essential hypertension. 229
Mechanics of the carotid artery wall and baroreflex sensitivity after acute ethanol administration in young healthy volunteers 226
Stimulation of cardiac apoptosis in ovariectomized hypertensive rats: potential role of the renin-angiotensin system 225
Peripheral adrenoceptors in hypotension of hemodialyzed uremic patients. 223
Apoptosis-inducing molecules and uses therefor 223
TRAIL shows potential cardioprotective activity. 221
The cardiac renin-angiotensin system in heart failure 219
Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failure. 219
[Activity and number of lymphocyte beta adrenergic receptors after protracted treatment with mepindolol sulfate of patients with essential arterial hypertension]. 219
Ace inhibition in renal disease: risks and benefits. 219
An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. 217
High-salt diet increases glomerular ACE/ACE2 ratio leading to oxidative stress and kidney damage 215
Initial Ablation Ratio Predicts Volume Reduction and Retreatment After 5 Years From Radiofrequency Ablation of Benign Thyroid Nodules 209
Reduction of blood pressure in obese hyperinsulinaemic hypertensive patients during somatostatin infusion 208
A case of cerebral salt wasting syndrome in a patient with central diabetes insipidus and status epilepticus 206
Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system. Endogenous antagonists 206
Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy 206
TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet-fed mouse 205
Il Transessualismo: identificazione di un percorso diagnostico e terapeutico. Kurtis Editrice, Milano 1999. 203
An ultrasonographic method to measure the sensitivity of the baroreflex in clinical practice: application to pharmacological studies. 203
TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation 203
Glomerular permeability defect in hypertension is dependent on renin angiotensin system activation. 203
Ambulatory blood pressure monitoring-derived short-term blood pressure variability in primary hyperparathyroidism 203
Baroreflex function after therapy withdrawal in patients with essential hypertension 199
Contribution of Systemic Blood-pressure To Myocardial Remodeling In Uremic Rats 199
Genetic polymorphisms of the renin-angiotensin-aldosterone system and renal insufficiency in essential hypertension 198
Ambulatory blood pressure monitoring-derived short-term blood pressure variability is increased in Cushing's syndrome. 198
Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. 196
TRAIL treatment prevents renal morphological changes and TGF-β-induced mesenchymal transition associated with diabetic nephropathy 196
[Adenylate cyclase activity--after stimulation of beta-receptors with isoproterenol--in relation to the presence or absence of monocytes in a population of mononucleated cells]. 194
Clinical Characterization and Predictive Factors for Progression in a Cohort of Patients with Interstitial Lung Disease and Features of Autoimmunity: The Need for a Revision of IPAF Classification Criteria 192
Ambulatory Arterial Stiffness Indexes in Cushing’s Syndrome 192
Changes in cardiac angiotensin converting enzyme after myocardial infarction and hypertrophy in rats 191
High salt diet ameliorates effects of angiotensin converting enzyme inhibition in spontaneously hypertensive streptozotocin diabetic rats 191
A case report of PTH elevation due to immunoassay interference 191
[Cardio-regulatory reflexes in patients with alcoholic liver cirrhosis]. 189
Meta-analysis on the effect of mild primary hyperparathyroidism and parathyroidectomy upon arterial stiffness 189
Increase in Mas1 Oncogene-Receptor Gene Expression in Colon Cancer 188
Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. 186
Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats 184
Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. 183
Salt blocks the renal benefits of ramipril in diabetic hypertensive rats 182
[Distensibility of large arteries after chronic treatment with nicardipine SR in aged hypertensive patients]. 182
TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases 181
Platelet alpha 2-adrenoceptor modifications induced by long-term treatment with indapamide in essential hypertension. 181
Localization of angiotensin converting enzyme in rat heart 180
Effects of prolonged high-altitude exposure on peripheral adrenergic receptors in young healthy volunteers. 180
Inhibition of angiotensin converting enzyme (ACE) in plasma and tissue 179
Totale 26.292
Categoria #
all - tutte 103.480
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 103.480


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021241 0 0 0 0 0 0 0 0 0 0 0 241
2021/20222.273 77 119 112 263 114 225 132 69 227 233 167 535
2022/20233.468 350 502 346 480 232 588 23 308 362 55 153 69
2023/20242.046 161 133 149 94 212 236 350 300 68 50 149 144
2024/20254.328 92 114 154 386 399 490 349 270 585 595 435 459
2025/202611.079 1.361 578 700 944 1.028 947 1.599 325 1.221 1.499 574 303
Totale 38.011